65MO Clinicopathological risk score following neoadjuvant imatinib predicts relapse-free survival in patients with GIST

Background: Eribulin (E) or Trabectedin (T) are standard active drugs in patients with advanced liposarcoma (aLip) after Adriamycin-based chemotherapy, however there are no comparative studies between them.Methods: Utilizing the TriNetX Global Collaborative Network, a platform that operates globally based on anonymized and aggregated clinical data, a sample of aLip patients from 128 healthcare organizations (HCOs) who met the initial criteria was selected.5year overall survival (OS) was analyzed between these cohorts using a Kaplan-Meier analysis.Hazard Ratio (HR) and its 95% confidence interval (95%CI) were calculated to evaluate the difference between cohorts.Propensity Score Matching (PSM) was used to balance the cohorts based on age, gender, and race mitigating possible cofounding variables.All statistical analyses were conducted utilizing the TriNetX Analytics function in the online research platform.Results: A total of 1828 patients met the study criteria and were included in our study.1240 received T and 588 received E therapy.After PSM, 558 patients in T arm and 558 in E arm were selected in order to compare OS. aLip patients treated with T and E showed a median OS of 401 and 347 days respectively.No OS differences was detected both previous to PSM and before PSM (post-PMS HR 0.0.955,95%CI 0.820-1.112,p0.614).Conclusions: In this study, based on Real World data, Trabectedin and Eribulin showed identical survival benefit in advanced Liposarcoma patients.To date this is the largest study comparison between this two therapeutic options.